Drug intelligence / Profile preview

nacom

Development stage: Unknown
Lead developer: Organon
Modality: Small Molecules
Administration: Oral

Overview

Nacom is a **combination pharmaceutical product containing carbidopa and levodopa**, used for the treatment of Parkinson's disease and parkinsonism syndromes. Levodopa acts as a precursor to dopamine, crossing the blood-brain barrier and being converted into dopamine to alleviate the motor symptoms resulting from dopaminergic neurodegeneration. Carbidopa is a dopa decarboxylase inhibitor that prevents peripheral breakdown of levodopa, increasing its availability in the brain and reducing side effects such as nausea. Nacom is formulated for oral administration and is used to manage symptoms like tremor, stiffness, and slowness of movement in Parkinson’s disease and similar disorders[1][7][9].

Brand names: nacom
Other names: nacom

Targets

DDC (Aromatic L-amino acid decarboxylase)

Beyond the preview

Go deeper on nacom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nacom.

Explore the full profile